预测新辅助治疗后胰腺导管腺癌切除患者总生存的列线图:MGH/MSK 开发与验证
研究基于在麻省总医院接受新辅助治疗后手术切除的胰腺导管腺癌患者数据开发列线图,并在纪念斯隆凯特琳队列中验证。多变量 Cox 回归识别年龄、CA19-9≥37 U/mL、肿瘤大小、淋巴结状态和 R1 切除为独立预后因素,列线图在 1、3、5 年总生存校准良好,两队列 C 指数分别为 0.729 和 0.712。
要点
- 列线图纳入年龄、CA19-9、肿瘤大小、淋巴结状态和 R1 切除五个预后因素。
- 模型在开发队列和外部验证队列的校正 C 指数分别为 0.729 和 0.712。
- 1、3、5 年总生存的校准图显示预测值与实际值高度一致。
核心结论
- 建立并验证了预测新辅助治疗后胰腺切除患者总生存的新列线图,有助于临床医生更准确估计该特定人群的生存。
研究设计与样本
- 回顾性分析麻省总医院接受新辅助治疗后手术切除的胰腺导管腺癌患者作为训练队列,共 325 例。
- 纪念斯隆凯特琳患者作为外部验证队列。
- 设计并训练预测总生存的列线图,采用 Bootstrap 法进行内部验证。
主要发现
- 多变量 Cox 回归显示年龄(HR 1.828,95%CI 1.251-2.246;P=.007)与总生存独立相关。
- 血清 CA19-9≥37 U/mL(HR 1.602,95%CI 1.187-3.258;P=.015)与总生存独立相关。
- 肿瘤大小(HR 2.278,95%CI 1.405-4.368;P=.003)与总生存独立相关。
- 淋巴结状态(HR 1.309,95%CI 1.108-2.439;P=.032)与总生存独立相关。
- R1 切除(HR 1.481,95%CI 1.049-2.091;P=.026)与总生存独立相关。
关键数值与推荐
- 列线图纳入年龄、CA19-9≥37 U/mL、肿瘤大小、淋巴结状态和 R1 切除五个变量。
- 麻省总医院队列校正 Harrel C 指数为 0.729,纪念斯隆凯特琳队列为 0.712。
- 校准图显示 1 年、3 年和 5 年总生存的预测值与实际值高度一致。
临床怎么用
- 可用于新辅助治疗后拟行或已行胰腺切除的胰腺导管腺癌患者,辅助个体化总生存评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prognostication in patients undergoing resection for pancreatic ductal adenocarcinoma following neoadjuvant therapy remains challenging. In this study, we aimed to develop and validate a nomogram for the prediction of overall survival of these patients. METHODS: Patients who underwent neoadjuvant therapy followed by surgical resection at the Massachusetts General Hospital were analyzed (training cohort). Patients from Memorial Sloan Kettering were included as a validation cohort. A nomogram to predict overall survival was designed, trained, and subjected to internal (bootstrap) validation. RESULTS: A total of 325 patients were identified from Massachusetts General Hospital. Multivariable Cox regression analysis demonstrated that age (hazard ratio 1.828, 95% confidence interval 1.251-2.246; P = .007), serum carbohydrate antigen 19-9 ≥ 37 U/mL (HR 1.602, 95% confidence interval 1.187-3.258; P = .015), tumor size (hazard ratio 2.278, 95% confidence interval 1.405-4.368; P = .003), nodal status (hazard ratio 1.309, 95% confidence interval 1.108-2.439; P = .032), and R1 tumor resection (hazard ratio 1.481, 95% confidence interval 1.049-2.091; P = .026) were independent factors associated with overall survival. A nomogram that incorporated these significant prognostic factors was established. The calibration plots demonstrated high concordance between predictive nomogram values and actual overall survival for 1-year, 3-year, and 5-year overall survival. The model demonstrated excellent discriminatory power in both the Massachusetts General Hospital and Memorial Sloan Kettering cohorts, with adjusted Harrel's concordance index values of 0.729 and 0.712, respectively. CONCLUSION: In this report, we established and validated a novel nomogram for predicting the survival of patients who underwent neoadjuvant therapy followed by pancreatectomy. This model allows clinicians to better estimate the survival of these specific patients.
引用
- Qiao G, Ilagan CH, Fernandez-Del Castillo C, et al. Development and validation of the Massachusetts General Hospital/Memorial Sloan Kettering nomogram to predict overall survival of resected patients with pancreatic ductal adenocarcinoma treated with neoadjuvant therapy. Surgery. 2022. PMID: 35931556. doi:10.1016/j.surg.2022.05.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。